# Fesoterodine for Amelioration of Autonomic Dysreflexia (AD) Following Spinal Cord Injury (SCI)

> **NCT02676154** · PHASE2 · COMPLETED · sponsor: **University of British Columbia** · enrollment: 15 (actual)

## Conditions studied

- Autonomic Dysreflexia

## Interventions

- **DRUG:** Fesoterodine

## Key facts

- **NCT ID:** NCT02676154
- **Lead sponsor:** University of British Columbia
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02-25
- **Primary completion:** 2019-01-31
- **Final completion:** 2019-01-31
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2019-09-09

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02676154

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02676154, "Fesoterodine for Amelioration of Autonomic Dysreflexia (AD) Following Spinal Cord Injury (SCI)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02676154. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*